In contrast, immune changes following anti-PD-1/PD-L1 therapy have been extensively analyzed in patient tissues, highlighting the roles of regulatory T cells and CXCL13 + T cells, though their precise localization and function within the tumor microenvironment (TME) remain unclear [24–29]. This evidence concerns the gene CXCL13 and neoplasm.